ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis

by Amy E. Hamaker • March 5, 2018

  • Tweet
  • Email
Print-Friendly Version

Comment: Recurrent respiratory papillomatosis (RRP) is a surgical disease for the majority of patients. When there is extensive tracheal and pulmonary spread, this benign disease process becomes very difficult to manage and can be fatal, and no standard systemic therapy has been shown to be consistently effective in the management of this disease process. This article reports the results of a national survey of the use of systemic bevacizumab for aggressive RRP. Eight patients were treated and all responded positively to the treatment. There were few reported complications. This study suggests that bevacizumab should be studied in a formal clinical trial for RRP. —Tanya K. Meyer, MD

You Might Also Like

  • Adjuvant Therapies May Increase Time Between Surgeries for Recurrent Respiratory Papillomatosis
  • Laryngeal Distribution of Recurrent Respiratory Papillomatosis
  • Prevalence of Dysplasia with Recurrent Respiratory Papillomatosis Is High
  • Adult-Onset Recurrent Respiratory Papillomatosis May Be Associated with Number of Sexual Partners
Explore This Issue
March 2018

What has been the initial experience of the use of systemic bevacizumab in the U.S. for recurrent RRP?

Bottom line: Systemic bevacizumab appears to have significant promise and a low complication profile for the most treatment-resistant and aggressive forms of papillomatosis.

Background: Complex laryngotracheal and pulmonary papillomatosis management has proven unsatisfying as there is no uniformity in responses to surgical and adjuvant therapies and, to date, no systemic therapy has been consistently effective. Responses to sublesional bevacizumab injections have been dramatic, but there are no clinical trials utilizing bevacizumab for RRP or standardized protocols for its dosing.

Study design: Case series performed through an electronic survey of the RRP Task Force of the American Society of Pediatric Otolaryngology, American Broncho-Esophagological Association, and physicians known to the authors to have used systemic bevacizumab for RRP. Eight completed surveys representing seven medical centers were available for analysis.

Setting: Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University, Baltimore, Md.

Synopsis: For the most part, patients had a long clinical history of juvenile onset RRP, with aggressive clinical courses requiring very frequent surgical interventions, in many cases at least once a month. Numerous adjuvant treatments had been previously administered, including intralesional cidofovir, systemic interferon, and celecoxib. The two adult-onset patients had primary pulmonary papilloma without an antecedent history of laryngeal papilloma. Dosing was initiated in all patients in the range of 5 to 10 mg/kg per dose, most frequently at three-week intervals. Seven of the eight patients were characterized by their physicians as having a partial response to treatment, with one complete response. In all patients, the surgical interval between excisions for papilloma was significantly lengthened after systemic bevacizumab, and in some cases surgical debridement was no longer necessary. The treatment appears to have been very well-tolerated in most patients, with only two reported minor complications (hemoptysis and proteinuria). Limitations included a selection bias, poor recall of patient or medication details, and incomplete data.

Citation: Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127:2225–2229.

Pages: 1 2 | Multi-Page

Filed Under: Laryngology, Literature Reviews Tagged With: bevacizumab, papillomatosis, recurrent respiratory papillomatosis, RRPIssue: March 2018

You Might Also Like:

  • Adjuvant Therapies May Increase Time Between Surgeries for Recurrent Respiratory Papillomatosis
  • Laryngeal Distribution of Recurrent Respiratory Papillomatosis
  • Prevalence of Dysplasia with Recurrent Respiratory Papillomatosis Is High
  • Adult-Onset Recurrent Respiratory Papillomatosis May Be Associated with Number of Sexual Partners

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Weaning Patients Off of PPIs
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.